Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2020 Oct 15;15(10):e0240491. doi: 10.1371/journal.pone.0240491

The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson’s disease

Ryota Tanaka 1,2,*, Kazuo Yamashiro 3, Takashi Ogawa 2, Genko Oyama 2, Kenya Nishioka 2, Atsushi Umemura 4, Yasushi Shimo 5, Nobutaka Hattori 2,*
Editor: Pasquale Abete6
PMCID: PMC7561175  PMID: 33057432

Abstract

Orthostatic hypotension (OH) frequently accompanies autonomic dysfunction and is an important risk factor for cognitive impairment in Parkinson’s disease (PD). While OH is usually diagnosed based on an orthostatic blood pressure drop, the association between the heart rate response and cognitive impairment remains unclear. We retrospectively analyzed 143 cases of clinically diagnosed PD to determine the association between the absence of a heart rate response and cognitive impairment in PD with OH. Among the patients with OH, neurogenic OH was diagnosed in cases without a heart rate increase, while all other patients were diagnosed with non-neurogenic OH. Dementia was found in 23 of 143 PD cases (16.1%) in this cohort. The presence of OH was an independent risk factor for dementia in PD in addition to the disease severity, years of education and beta-blockers use. Neurogenic OH was significantly associated with dementia compared to the no OH group (hazard ratio [HR] 7.3, 95% confidence interval [CI] 2.2–24.6, P<0.01), an association that was preserved after adjusting for age, gender and other covariant factors. However, no such association was observed for non-neurogenic OH (HR 2.9, 95%CI 0.8–10.9, P = 0.12). While the cognitive impairment was significantly worse in the neurogenic OH group than the no-OH group, the groups were otherwise similar. The blood pressure decrease was significantly lower in both OH groups than in the no-OH group, despite no significant differences between the OH groups. Our finding showed that OH without a heart rate response was an important predictor of cognitive impairment in PD.

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder with a middle-age onset, and it manifests as progressive motor symptoms, including bradykinesia, muscular rigidity, tremor at rest, and postural or gait disturbance [1, 2]. Non-motor symptoms, such as cognitive decline and autonomic dysfunction, are important factors that also affect the prognosis of PD [3, 4].

Orthostatic hypotension (OH) is one of the most frequently observed examples of autonomic dysfunction in PD [5]. OH is usually classified into sub-types of neurogenic OH, which shows decrease in the orthostatic blood pressure (BP) without a compensatory heart rate increase, and non-neurogenic OH, which does show a heart rate increase. Lewy body pathology associated with cardiovascular autonomic dysfunction causes neurogenic OH in PD [5], while non-neurogenic OH is usually caused by hypovolemia and cardiac pump failure.

The existence of OH has been associated with falling, and the prodrug to norepinephrine has been shown to reduce the risk of falling in cases of PD [6, 7]. Furthermore, the coexistence of OH and other autonomic dysfunctions in PD was found to be associated with a poorer survival rate over long-term observation [8, 9]. Cognitive decline and dementia are also important factors affecting the prognosis of PD [10, 11]. Approximately 30% of PD patients develop dementia, and OH has been consider an independent risk factor for cognitive decline, along with one’s age, an older age at onset, akinetic-rigid subtypes, and non-motor symptoms such as visual hallucination and, rapid eye movement sleep behavior disorders in PD [12].

While OH is usually diagnosed based on a decrease in BP within 3 minutes after rising from a supine position, the absence of a heart rate increase is an important response for discriminating neurogenic OH from non-neurogenic OH [13]. However, few studies have assessed the association between the presence or absence of heart rate response and cognitive decline in cases of PD with OH.

In the present study, we assessed whether or not the absence of heart rate increase was a risk factor for dementia in PD patients with OH.

Material and methods

We used a retrospective cohort to analyze the association between OH and dementia in PD. We conducted a retrospective review of 172 patients with PD admitted to Juntendo University Hospital for a diagnostic assessment, drug adjustment, or evaluation for deep-brain stimulation between January 2014 and October 2017. We excluded patients with PD admitted for the treatment of acute illnesses, such as acute infection and ileus, and also excluded patients with PD who had congestive heart failure and diabetes mellitus. The diagnosis of PD was made according to the UK Brain Bank criteria [1].

Of the 172 participants, 20 were excluded due to the absence of an OH evaluation or cognitive assessment. We also excluded nine patients who had already received anti-hypotensive medication. We collected the baseline characteristic of patients, such as the age, duration of disease, Hoehn-Yahr stage (H-Y), body mass index (BMI), history of hypertension, stroke, coronary artery disease, peripheral artery disease, and anti-hypertensive medication such as angiotensin converting enzyme inhibitors (ACE-Is). angiotensin II receptor blockers (ARBs), calcium channel blocker (CCBs), beta blockers, and diuretics using medical records. We also calculated the levodopa equivalent daily dose (LEDD) for each participant.

We obtained oral informed consent from the participants and provided patients with the opportunity to opt out. The study protocol was approved by the ethics committee of Juntendo University Hospital.

OH and supine hypertension (SH)

After at least 15 minutes resting in the supine position, the BP was measured, using an electronic sphygmomanometer (ES-H55; Terumo, Tokyo, Japan). The first measurement was taken while the patient remained supine, followed by a BP assessment in a standing position. OH was defined as a 20-mmHg drop in systolic BP and/or a 10-mmHg drop in diastolic BP within the first 3 minutes after standing.

The baseline supine and the lowest orthostatic values for blood pressure were recorded. Furthermore, we determined the maximum increase in heart rate within 3 minutes after postural change. If the patient’s heart rate (HR) increase was < 15 beats per minute, we diagnosed them with neurogenic OH, whereas if the patient’s HR increase was ≥ 15 beats per minute, we diagnosed them with non-neurogenic OH.

SH was defined as a systolic BP of ≥140 mmHg or a diastolic BP of ≥90 mmHg, when in the supine position.

The cognitive assessment and diagnosis of dementia

The cognitive function was assessed using the Mini-Mental State Examination (MMSE), the Hasegawa dementia scale-revised (HDS-R), and the Montreal Cognitive Assessment (MoCA). We enrolled PD with dementia (PDD) patients but not dementia with Lewy bodies (DLB) patients based on the “one-year rule” [14], and the diagnosis of PDD was based on the diagnostic criteria from the Movement Disorder Society Task Force [15].

Detection of cerebrovascular lesions

Brain magnetic resonance imaging (MRI) was performed using a 1.5-T MR system (Vistart RX; Toshiba, Japan). The whole brain was scanned at a slice thickness of 5.5mm with an interslice gap of 1mm; 20 axial images were obtained. The imaging protocol consisted of axial fluid-attenuated inversion recovery (FALIR) images for small vessel disease. Deep white matter hyperintensity (DWMH), was also assessed with MRI using semiquantitative visual scales [16].

Statistical analyses

Continuous variables were compared using either Student’s t-test or one-way ANOVA with Dunnett’s multiple comparison post hoc test. The frequency of categorical variables was compared using the χ2 test. We performed multivariate logistic regression analyses to evaluate the association of dementia with OH and the heart rate response. Clinical variables that were significant following a univariate analysis were included. The statistical analyses were performed using the JMP Version 14.2 software program (SAS Inc., Cary, NC, USA). A value of P <0.05 was considered to be statistically significant.

Result

Baseline demographics and risk for dementia in PD

Table 1 shows the baseline demographics and the medical history of the enrolled PD patients. Of the 143 patients, 23 (16.1%) had dementia. The age, H-Y stage, cumulative years of education, and history of coronary artery disease (CAD) were significantly associated with dementia in PD patients. OH and SH were also associated with dementia, although there was no significant difference in the WMH scores on MRI between PD and PD with dementia (PDD). Each test related to cognitive function was significantly lower in the group with dementia than in the group without dementia. The LEDD was similar between the groups of PD and PDD. There were no significant differences in the use of anti-hypertensive medications, except for beta-blocker between PD and PDD.

Table 1. The comparison of the baseline characteristics between PD and PDD.

PD PDD P value
N = 143 120 (83.9%) 23 (16.1%)
Age, y 62.4±10.3 70.3±9.3 <0.001
Onset of age 51.3±11.7 61.0±11.2 <0.001
Gender (F) 71 (59.2%) 9 (39.1%) NS
Duration of disease, y 11.2±6.7 9.3±6.0 NS
H-Y stage 2.8±0.8 3.5±0.9 <0.001
BMI 21.8±3.6 21.2±3.8 NS
Education, y 13.6±2.2 12.1±3.1 <0.01
Hypertension, (%) 24 (20.0%) 8 (34.8%) NS
Stroke, (%) 2 (1.7%) 2 (8.7%) NS
Coronary artery disease, (%) 1 (0.8%) 2 (8.7%) <0.05
Peripheral artery disease, (%) 0 0 NS
Orthostatic hypotension, (%) 59 (49.2%) 19 (82.6%) <0.01
Supine hypertension, (%) 14 (11.7%) 8 (34.8%) <0.01
DWMH 0.7±0.7 1.0±0.9 NS
LEDD 970.5±402.5 882.2±234.8 NS
ACE-I/ARB 13 (10.8%) 1 (4.4%) NS
Ca-blocker 10 (8.3%) 5 (21.7%) NS
Beta-blocker 1 (0.8%) 3 (13.0%) <0.01
Diuretics 2 (1.7%) 0 NS
HDS-R 28.0±1.9 19.1±5.7 <0.0001
MMSE 28.4±1.6 21.3±3.8 <0.0001
MoCA-J 25.7±2.9 16.0±4.0 <0.0001
Open in a new tab

The univariate analysis for the risk of dementia in PD showed a significant association with the age, H-Y stage, years of education, OH, SH and beta-blocker use (Table 2).

Table 2. The results of multivariable logistic regression analysis for the risk of dementia in PD.

Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Age, per unit 1.1 1.0–1.2 <0.001 1.1 0.9–1.2 NS
H-Y, per unit 3.2 1.6–6.2 <0.001 2.6 1.2–5.9 <0.05
Education, per unit 0.8 0.6–0.9 <0.01 0.7 0.5–0.9 <0.05
CAD 11.3 0.9–130.7 NS - - -
OH 4.9 1.6–15.3 <0.01 8.9 1.6–49.0 <0.05
SH 4.0 1.5–11.2 <0.01 1.5 0.4–6.2 NS
Beta-blocker use 17.8 1.8–180.2 <0.05 456.9 8.3–25304.2 <0.01
Open in a new tab

The multivariate odds ratios (ORs) for dementia in PD patients were significantly higher for the H-Y stage (Table 2, OR 2.6 per unit, 95% confidence interval [CI] 1.2–5.9, P<0.05), OH (Table 2, OR 8.9, 95% CI 1.6–49.0, P<0.05), and beta-blocker use (Table 2, OR 456.9, 95% CI 8.2–25304.2, P<0.01). In contrast, the ORs for dementia were significantly lower for years of education (Table 2, OR 0.7, 95% CI 0.5–0.9, P<0.05).

The association between the orthostatic HR response and dementia in PD patients with OH

We divided OH into the two sub-types of neurogenic OH, in which the HR increase is < 15 beats per minute, and non-neurogenic OH in which the HR increase is ≥ 15 beats per minute. We then compared the differences in the risk for dementia between the no-OH group and each OH group (Table 3). The univariate ORs for dementia were significantly higher in the neurogenic OH group than the no-OH group (OR 7.3, 95% CI 2.2–24.6, P<0.01). This difference remained significant after adjusting for the age, sex, H-Y stage, and years of education (model 1; OR 5.6, 95% CI 1.3–24.9, P<0.05) as well as for beta-blocker use (model 2; OR 11.5, 95% CI 1.6–85.1, P<0.05). We noted no significant differences in dementia between the non-neurogenic OH group and the no-OH group (OR 2.9, 95% CI 0.8–10.9, P = 0.12, model 1; OR 4.4, 95% CI 0.8–23.8, P = 0.08); however, there was a significant association after adjusting for beta-blocker use (model 2; OR 12.9, 95% CI 1.4–114.6, P<0.05).

Table 3. The results of multivariable logistic regression analysis for the risk of dementia based on the type of orthostatic hypotension.

Univariate Multivariate (model 1) Multivariate (model 2)
HR 95% CI P HR 95% CI P HR 95% CI P
OH (-) 1 (reference) 1 (reference) 1 (reference)
Non-neurogenic OH 2.9 0.8–10.9 NS 3 0.7–12.4 NS 12.9 1.4–114.6 <0.05
Neurogenic OH 7.3 2.2–24.6 <0.01 5.3 1.5–18.8 <0.05 11.5 1.6–85.1 <0.05
Open in a new tab

A comparison of the associated factors and cognitive impairment among patients without OH and with non-neurogenic or neurogenic OH

We used Dunnett’s test to compare the factors associated with dementia and three independent cognitive scores among no-OH group and both OH subtypes (Table 4). The age and disease severity (H-Y score) were significantly higher in the neurogenic OH group than in the no-OH group. However, these associations were not observed between the non-neurogenic OH and no-OH groups. We also found respective significant differences in the presence of SH (4.6% vs. 10.5% vs. 37.5%, P<0.0001) and prevalence of dementia among patients with no-OH, non-neurogenic OH, and neurogenic OH (6.2% vs 15.8% vs 32.5%, P<0.01). The value of each cognitive score was lower in the neurogenic OH group than in the no-OH or no-neurogenic OH group. All cognitive scores differed significantly between the no-OH and neurogenic OH group, but we found no such association between no-OH and non-neurogenic OH groups (Table 4). While the blood pressure decrease was significantly lower in the both OH groups than in the no-OH group, there were no significant differences between the OH subtype groups (Table 4).

Table 4. The comparison of the associated factors and cognitive impairment among patients without OH and with non-neurogenic or neurogenic OH.

No OH Non-neurogenic OH Neurogenic OH P value
N = 143 65 38 40
Age 61.5±11.4 61.7±9.8 69.3±7.1a <0.001
Disease duration 9.8±4.9 12.2±8.5 11.4±6.8 NS
H-Y 2.8±0.8 2.6±0.8 3.4±0.8a <0.001
Education (y) 13.6±2.5 13.2±2.4 13.2±2.4 NS
HT 16 (24.6%) 4 (10.5%) 12 (30.0%) NS
SH 3 (4.6%) 4 (10.5%) 15 (37.5%) <0.0001
DWMH 0.68±0.69 0.70±0.70 0.92±0.81 NS
LED 907.6±371.5 1013.0±346.6 981.6±425.6 NS
Beta-blocker 3 (4.6%) 0 1 (2.5%) NS
Dementia 4 (6.2%) 6 (15.8%) 13 (32.5%) <0.01
HDS-R 27.5±3.7 26.6±4.4 25.2±4.9a <0.05
MMSE 28.1±2.8 27.4±3.0 25.7±4.1a <0.01
MoCA 25.2±4.3 24.8±4.0 21.9±5.3a <0.01
ΔSBP -2.0±11.0 -31.3±14.9a -31.5±21.2a <0.001
ΔDBP 3.8±7.0 -15.7±9.1a -17.8±10.7a <0.001
Open in a new tab

a significant differences compare to no OH groups.

Discussion

Although a previous systematic review article revealed the estimated prevalence of OH in PD patients to be 30.1% [17], the prevalence of OH was 54.5% in our cohort. The prevalence rate across studies has been reported to range from 9.6% to 64.9% and seems to be influenced by covariant factors, such as the age and disease duration [17]. As the disease duration (10.9 ± 6.6 years) at the assessment in the present study was relatively long, this might have increased the prevalence of OH in our cohort.

Although the association between OH and cognitive decline has been inconclusive, a recent meta-analysis of prospective cohort data showed the OH increased the risk of dementia, and this trend was preserved in two subtypes of dementia: Alzheimer’s disease (adjusted pooled hazard ratio 1.175, 95% CI 1.022–1.351) and vascular dementia (adjusted pooled hazard ratio 1.403, 95% CI 1.042–1.889) [18].

Both OH and cognitive impairment may reflect common brain and peripheral neurodegeneration as well as its severity in PD [3, 19]. The anterior cingulate cortex has been proposed as an important site for cognitive and autonomic impairment [3]. The loss of integrity and atrophy in cingulate structural covariance networks has been associated with non-dopaminergic features, such as cognitive impairment and excessive daytime sleepiness [20]. The locus ceruleus, which is the sole source of noradrenaline, is also frequently affected in PD. Noradrenaline acts as a neuromodulator of multiple affected areas in the forebrain and influences the memory in attention or retrieve information [21]. Sommerauer et al. studied the association between the noradrenergic system and cognitive decline or OH in PD. They showed that a reduction in noradrenaline transporter on 11C-MeNER PET was associated with cognitive performance and OH [22].

The possible mechanisms underlying the cognitive impairment by OH are suspected to be multifactorial, but the most frequently proposed mechanism involves recurrent episodic brain hypoxia/ischemia. The cerebrovascular pathology and condition of ischemia/hypoxia are important pathogenic mechanisms underlying the development of neurodegeneration in dementia patients including α-synucleinopathies [23]. Interestingly, experimental models of brief cerebral blood flow reduction have promoted the aggregation of alpha-synuclein, which is associated with extensive neuronal cell death and large infarction [24]. These findings suggest that recurrent episodic brain ischemia/hypoxia induced by OH may indicate an increased risk of extensive aggregation of α-synuclein and thereby be associated with cognitive decline in PD patients.

Furthermore, brain hypoxia/ischemia by OH might induce development of small vessel disease in the brain. WMH on MRI is significantly more frequent in cases of OH, SH or both than in patients with neither among PD cases [25]. Our results also showed WMH was more severe in cases of neurogenic OH than in the no-OH or non-neurogenic OH patients, without statistical significance.

Cerebral microbleeds (CMBs) are also well-known markers of small vessel disease that can be detected on T2*-weighted gradient echo of MRI. CMBs are often observed in PD patients, and the presence of OH was found to be an independent risk factor for CMBs in our previous report [26]. CMBs were also significant greater risks for cognitive impairment in PD [27]. These small vessel diseases are thought to increase the neuroinflammation and deteriorate the pathology of α-synucleinopathies [23].

SH is often companied by OH in neurodegenerative disorders with autonomic dysfunction [19], and the neurogenic OH group showed a significantly higher prevalence of SH than no-OH and non-neurogenic OH in our cohort. Because CMBs are more abundant in cases of OH accompanied by SH than in OH without SH among PD patients [28], SH rather than OH may increase the susceptibility of end-organ damage and small vessel disease related to cognitive impairment in PD.

Our results showed that the absence of a heart rate increase was an important predictor of cognitive impairment. Walters et al. reported that the OH was associated with an increase in the long-term risk of dementia in a population-based prospective study, and the risk of dementia was markedly increased in those with OH who lacked a compensatory increase in the HR [29]. The lack of an HR increase may reflect the severity of autonomic dysfunction; however, we found no significant differences in the orthostatic drop in BP between neurogenic and non-neurogenic OH. As the risk of dementia was markedly increased in OH patients who lacked a compensatory increase in their HR, the formal assessment of the OH incorporation of the HR response is important for determining the severity of autonomic dysfunction and predicting cognitive impairment in PD patients.

Finally, our data showed that beta-blocker use was associated with PDD and non-neurogenic OH was also associated with dementia after adjusting for beta-blocker use. In this cohort study, beta-blocker use was found in only four patients, including two patients who used these agents for hypertension and another two patients who used them for tremor. The association between beta-blocker use and cognitive impairment has remained inconclusive [30, 31], and further larger scale studies will be needed to explore whether or not beta-blocker use is involved in the cognitive impairment in PD.

While we demonstrated an association between absence of heart rate increase and cognitive impairment in PD with OH, several limitations remain to be disclosed. Because of the retrospective nature study and the small patient population, further prospective studies in large population are warranted. Second, we did not review the data of syncope or unexplained fall in this study. Syncope and unexplained fall are important related symptoms of OH and are frequently observed in patients with dementia [32]. Further studies are also warranted to determine whether or not suffering from syncope or unexplained fall is related to cognitive impairment in PD.

In conclusion, this study showed that OH without an HR response was an important marker of cognitive impairment in PD. Further prospective studies should be conducted to clarify whether or not the HR response predicts cognitive decline.

Data Availability

All relevant data are within the paper.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–184. 10.1136/jnnp.55.3.181 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2013;84 (4):409–15. 10.1136/jnnp-2012-303455 . [DOI] [PubMed] [Google Scholar]
  • 3.McDonald C, Newton JL, Burn DJ. Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association? Mov Disord. 2016;31(7):937–46. 10.1002/mds.26632 . [DOI] [PubMed] [Google Scholar]
  • 4.Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20(10):1255–63. 10.1002/mds.20527 [DOI] [PubMed] [Google Scholar]
  • 5.Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol. 2016;15 (9):954–966. 10.1016/S1474-4422(16)30079-5 [DOI] [PubMed] [Google Scholar]
  • 6.Rudzińska M, Bukowczan S, Stożek J, Zajdel K, Mirek E, Chwała W, et al. Causes and consequences of falls in Parkinson disease patients in a prospective study. Neurol Neurochir Pol. 2013;47(5):423–30. 10.5114/ninp.2013.38222 [DOI] [PubMed] [Google Scholar]
  • 7.Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol. 2016;39(5):220–6. 10.1097/WNF.0000000000000168 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: A prospective cohort study. Neurology. 2015;85 (18):1554–61. 10.1212/WNL.0000000000002086 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol.2017;74(8):970–976. 10.1001/jamaneurol.2017.1125 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, et al. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism Relat Disord. 2014;20(10):1071–5. 10.1016/j.parkreldis.2014.07.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Agüera-Ortiz L, Weintraub D, et al. Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. Parkinsonism Relat Disord. 2015;21(6):629–34. 10.1016/j.parkreldis.2015.03.024 . [DOI] [PubMed] [Google Scholar]
  • 12.Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697–707. 10.1016/S1474-4422(12)70152-7 . [DOI] [PubMed] [Google Scholar]
  • 13.Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69–72. 10.1007/s10286-011-0119-5 . [DOI] [PubMed] [Google Scholar]
  • 14.McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863–72. 10.1212/01.wnl.0000187889.17253.b1 . [DOI] [PubMed] [Google Scholar]
  • 15.Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689–1707. 10.1002/mds.21507 . [DOI] [PubMed] [Google Scholar]
  • 16.Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Roentgenol. 1987;149(2):351–6. 10.2214/ajr.149.2.351 . [DOI] [PubMed] [Google Scholar]
  • 17.Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724–9. 10.1016/j.parkreldis.2011.04.016 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Min M, Shi T, Sun C, Liang M, Zhang Y, Wu Y, et al. 10.1002/gps.4964 Int J Geriatr Psychiatry. 2018;33(12):1541–1547. [DOI] [PubMed] [Google Scholar]
  • 19.Udow SJ, Robertson AD, MacIntosh BJ, Espay AJ, Rowe JB, Lang AE, et al. 'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? J Neurol Neurosurg Psychiatry. 2016;87(12):1311–1321. 10.1136/jnnp-2016-314123 . [DOI] [PubMed] [Google Scholar]
  • 20.de Schipper LJ, van der Grond J, Marinus J, Henselmans JML, van Hilten JJ. Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson's disease. Neuroimage Clin. 2017;15:587–593. 10.1016/j.nicl.2017.05.012 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10(3):211–23. 10.1038/nrn2573 . [DOI] [PubMed] [Google Scholar]
  • 22.Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J, et al. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 2018;141(2):496–504. 10.1093/brain/awx348 [DOI] [PubMed] [Google Scholar]
  • 23.Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016;36(1):172–86. 10.1038/jcbfm.2015.164 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, Lule S, Gurer G, Can A, et al. Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab. 2011;31(3):913–23. 10.1038/jcbfm.2010.170 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kim Joong-Seok, Oh Yoon-Sang, Lee Kwang-Soo, Kim Yeong-In, Yang Dong-Won, Goldstein David S. Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology. 2012;79(13):1323–1331. 10.1212/WNL.0b013e31826c1acd . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yamashiro K, Tanaka R, Hoshino Y, Hatano T, Nishioka K, Hattori N. The prevalence and risk 10.1016/j.parkreldis.2015.06.019 of cerebral microbleeds in patients with Parkinson's disease. Parkinsonism Relat Disord. 2015;21(9):1076–81. [DOI] [PubMed] [Google Scholar]
  • 27.Daida K, Tanaka R, Yamashiro K, Ogawa T, Oyama G, Nishioka K, et al. The presence of cerebral microbleeds is associated with cognitive impairment in Parkinson's disease. J Neurol Sci. 2018;393:39–44. 10.1016/j.jns.2018.08.009 . [DOI] [PubMed] [Google Scholar]
  • 28.Yamashiro K, Tanaka R, Shimo Y, Oyama G, Ogawa T, Umemura A, et al. Cerebral microbleeds and blood pressure abnormalities in Parkinson's disease. eNeurologicalSci. 2017;10:5–11. 10.1016/j.ensci.2017.12.002 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wolters FJ, Mattace-Raso FU, Koudstaal PJ, Hofman A, Ikram MA; Heart Brain Connection Collaborative Research Group. Orthostatic Hypotension and the Long-Term Risk of Dementia: A Population-Based Study. PLoS Med. 2016;13(10) e1002143 10.1371/journal.pmed.1002143 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, White LR; Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81:888–95. 10.1212/WNL.0b013e3182a351d4 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Holm H, Ricci F, Di Martino G, Bachus E, Nilsson ED, Ballerini P, et al. Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. Vascul Pharmacol. 2020. Feb-Mar;125–126:106649 10.1016/j.vph.2020.106649 . [DOI] [PubMed] [Google Scholar]
  • 32.Ungar A, Mussi C, Ceccofiglio A, Bellelli G, Nicosia F, Bo M, et al. Etiology of Syncope and Unexplained Falls in Elderly Adults with Dementia: Syncope and Dementia (SYD) Study. J Am Geriatr Soc. 2016;64:1567–73. 10.1111/jgs.14225 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Pasquale Abete

17 Aug 2020

PONE-D-20-22293

The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson’s disease

PLOS ONE

Dear Dr. TANAKA,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 01 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Pasquale Abete

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following in the Financial Disclosure section:

[R.T. reports personal fees from honoraria: not related to the current work: Takeda Pharmaceutical Co.,Ltd., Nippon Boehringer Ingelheim,Co.,Ltd, Dai-Nippon Sumitomo Pharma Co.,Ltd., Bayer Yakuhin, Ltd, Otsuka Pharmaceutical, Co.,Ltd, Pfizer Japan Inc., , DAIICHI SANKYO Co.,Ltd., Eisai Co.,Ltd., Bristol-Myers Squibb Co., Stryker Japan K.K., CSL Behring K.K. and Kowa Co.,Ltd.

K.Y. reports grants from Grants from Grant-in-Aid for Scientific Research, and personal fees from honoraria for work unrelated to the current study: Pfizer Inc,, Takeda Pharmaceutical Co.,Ltd., Dai-Nippon Sumitomo Pharma Co.,Ltd., Bayer Yakuhin, Ltd, Otsuka Pharmaceutical, Co.,Ltd., DAIICHI SANKYO Co.,Ltd., and Novartis Pharma K.K.

T.O. reports the following disclosures: None

K.N. reports the following disclosures: Grant from Japan Society for the Promotion of Science (JSPS) KAKENHI Grant and a research grant from Biogen Japan Ltd. not granted for the current study.

G.O. reports grants from Grants from Japan Society for the Promotion of Science; Grant-in-Aid for Young Scientists (B), honoraria from work unrelated to the current study: Medtronic, Boston Scientific, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Novartis Pharma, MSD, Nihon Medi-Physics, FP Pharmaceutical Corporation, Kyowa Hakko Kirin, and Abbvie.

A.U. reports grants from Grants from Japan Society for the Promotion of Science; Grant-in-Aid for Scientific Research (C), Research Grant from Novartis Pharma K.K, consultancy: Boston Scientific Japan, and honoraria: Medtronic Japan Inc., Novartis Pharma K.K, Kyowa Hakko-Kirin Co.,Ltd., Takeda Pharmaceutical Co.,Ltd. And Abbvie, for work unrelated to the current study.

Y.S. reports grants from the Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research and speaker honoraria from Medtronic, Boston Scientific, Otsuka Pharmaceutical, Takeda Pharmaceutical CO, Sumitomo Dainippon Pharma, Novartis Pharma, MSD, FP Pharmaceutical Corporation, Kyowa Hakko Kirin, and AbbVie, Inc

N.H. reports grants from the Japan Society for the Promotion of Science (JSPS); grants from Ministry of Education Culture,Sports,Science and Technology Japan, grants from Health Labour Sciences Research Grant, grants from Japan Agency for Medical Research and Development (AMED), AbbVie GK, FP Pharma. Co, Dai-Nippon Sumitomo Pharma Co.,Ltd, Eisai Co.,Ltd., and received honoraria of as a speaker and advisory boards from Kyowa Kirin Co., Ltd., Dai-Nippon Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical, Co., Ltd, AbbVie GK, Eisai Co., Ltd., FP Pharma. Co, Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical, Novartis Pharma, MSD, Nihon Medi-Physics, Bristol-Myers Squibb Company, Ono Pharmaceutical Co., Ltd., EA Pharma Co., Ltd, Asahi Kasei Medical Co., Ltd., and Chugai Pharma Manufacturing Co., Ltd.

Also he received honoraria from Biogen Japan Ltd for Subcontracting (Trial cases) and he has  the Equity stock (8%) of PARKINSON Laboratories Co. Ltd.]. 

We note that you received funding from multiple commercial sources.

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

Additional Editor Comments (if provided):

The authors retrospectively analyzed 147 cases of clinically diagnosed PD to determine the association between the absence of a heart rate response and cognitive impairment in PD with OH. Among the patients with OH, neurogenic OH was diagnosed in cases without a heart rate increase, while all other patients were diagnosed with nonneurogenicOH. Dementia was found in 25 of 147 PD cases (17%) in this cohort. The presence of OH was an independent risk factor for dementia in PD in addition to the disease severity and years of education. Neurogenic OH was significantly associated with dementia compared to the no OH group (harzard ratio [HR] 8.2, 95% confidence interval [CI] 2.5-26.9, P<0.001), an association that was preserved after adjusting for age, gender and other covariant factors. However, no such association was observed for non-neurogenic OH (HR 2.7, 95%CI 0.7-10.5, P=0.13). While the cognitive impairment was significantly worse in the neurogenic OH group than the no-OH group, the groups were otherwise similar. The blood pressure decrease was significantly lower in both OH groups than in the no-OH group, despite no significant differences between the OH groups.

The manuscript is interesting. However, I have a concern regarding the presence of syncope and/or unexplained falls in this sample. Please see and discuss Ungar A: Etiology of Syncope and Unexplained Falls in Elderly Adults with Dementia: Syncope and Dementia (SYD) Study. J Am Geriatr Soc. 2016 Aug;64(8):1567-73.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper is of interest and the association between orthostatic hypotension (OH) , cognitive impairment and Parkinson’s disease (PD) is clinically relevant. The association between the heart rate response and cognitive impairment was retrospectively analyzed in 147 cases of clinically diagnosed PD to determine the association between the absence of a heart rate response and cognitive impairment in PD with OH. Among the patients with OH, neurogenic OH was diagnosed in caseswithout a heart rate increase, while all other patients were diagnosed with non-neurogenic OH. Dementia was found in 25 of 147 PD cases (17%). Neurogenic OH was significantly associatedwith dementia compared to the no OH group (harzard ratio [HR] 8.2, 95% confidenceinterval [CI] 2.5-26.9, P<0.001), an association that was preserved after adjusting forage, gender and other covariate. No association was observedfor non-neurogenic OH (HR 2.7, 95%CI 0.7-10.5, P=0.13). The manuscript is well written, data support conclusions.

Reviewer #2: The paper is interesting, resulting in a great impact on management of PD patients. The correlation of dementia in PD patients with neurogenic OH is a relevant finding to better understand evolution and prognosis of PD. However, some aspects should be more extensively argued to avoid confounding data.

Major revision

Materials and methods: In this study, drugs were not considered with exception of anti-hypotensive medications and levodopa. The influence of some classes of medications on postural response of arterial pressure is well known. In particular, there is no mention about beta-blockers. Patients with congestive heart failure were excluded from the study, but use of beta-blockers is also and often requested in hypertensive patients or in coronary artery disease (enrolled in this study). This class of medications could fade postural heart rate response leading to a wrong diagnosis of neurogenic OH.

The study should be improved by adding data on medications to avoid that the association of neurogenic OH with dementia in PD patients is considered only a winsome suggestion.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Oct 15;15(10):e0240491. doi: 10.1371/journal.pone.0240491.r002

Author response to Decision Letter 0

14 Sep 2020

Response to reviewers,

Additional Editor Comments (if provided):

The authors retrospectively analyzed 147 cases of clinically diagnosed PD to determine the association between the absence of a heart rate response and cognitive impairment in PD with OH. Among the patients with OH, neurogenic OH was diagnosed in cases without a heart rate increase, while all other patients were diagnosed with nonneurogenicOH. Dementia was found in 25 of 147 PD cases (17%) in this cohort. The presence of OH was an independent risk factor for dementia in PD in addition to the disease severity and years of education. Neurogenic OH was significantly associated with dementia compared to the no OH group (harzard ratio [HR] 8.2, 95% confidence interval [CI] 2.5-26.9, P<0.001), an association that was preserved after adjusting for age, gender and other covariant factors. However, no such association was observed for non-neurogenic OH (HR 2.7, 95%CI 0.7-10.5, P=0.13). While the cognitive impairment was significantly worse in the neurogenic OH group than the no-OH group, the groups were otherwise similar. The blood pressure decrease was significantly lower in both OH groups than in the no-OH group, despite no significant differences between the OH groups.

The manuscript is interesting. However, I have a concern regarding the presence of syncope and/or unexplained falls in this sample. Please see and discuss Ungar A: Etiology of Syncope and Unexplained Falls in Elderly Adults with Dementia: Syncope and Dementia (SYD) Study. J Am Geriatr Soc. 2016 Aug;64(8):1567-73.

Response:

We thank the editor for the important suggestion concerning the presence of syncope and unexplained fall in this study. Unfortunately, we did not collect information on syncope or unexplained fall in this study, so we could not analyze these issues. However, as the editor indicated, whether or not syncope and unexplained fall are risks for dementia and the relationship between orthostatic hypotension and syncope or unexplained fall in PD are clinically important issues. We have now mentioned this in the Discussion of the revised manuscript (page 18, line 267-271, page 198, line 272).

Reviewer #1: The paper is of interest and the association between orthostatic hypotension (OH) , cognitive impairment and Parkinson’s disease (PD) is clinically relevant. The association between the heart rate response and cognitive impairment was retrospectively analyzed in 147 cases of clinically diagnosed PD to determine the association between the absence of a heart rate response and cognitive impairment in PD with OH. Among the patients with OH, neurogenic OH was diagnosed in caseswithout a heart rate increase, while all other patients were diagnosed with non-neurogenic OH. Dementia was found in 25 of 147 PD cases (17%). Neurogenic OH was significantly associatedwith dementia compared to the no OH group (harzard ratio [HR] 8.2, 95% confidenceinterval [CI] 2.5-26.9, P<0.001), an association that was preserved after adjusting forage, gender and other covariate. No association was observedfor non-neurogenic OH (HR 2.7, 95%CI 0.7-10.5, P=0.13). The manuscript is well written, data support conclusions.

Rensponse:

We thank the reviewer for this positive evaluation. In accordance with the comment from the academic editor and Reviewer 2, we modified the manuscript accordingly.

Reviewer #2: The paper is interesting, resulting in a great impact on management of PD patients. The correlation of dementia in PD patients with neurogenic OH is a relevant finding to better understand evolution and prognosis of PD. However, some aspects should be more extensively argued to avoid confounding data.

Major revision

Materials and methods: In this study, drugs were not considered with exception of anti-hypotensive medications and levodopa. The influence of some classes of medications on postural response of arterial pressure is well known. In particular, there is no mention about beta-blockers. Patients with congestive heart failure were excluded from the study, but use of beta-blockers is also and often requested in hypertensive patients or in coronary artery disease (enrolled in this study). This class of medications could fade postural heart rate response leading to a wrong diagnosis of neurogenic OH.

The study should be improved by adding data on medications to avoid that the association of neurogenic OH with dementia in PD patients is considered only a winsome suggestion.

Response:

First, we reviewed the data and found four patients had been treated with midodrine during the investigation. We apologize for our mistake, and those four patients have been excluded from this study. As the reviewer suggested, we reviewed the data again and added the information on anti-hypertensive medications such as angiotensin-converting-enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), beta blockers, and diuretics. There were no patients who were treated with ACE-Is. There were no significant differences in the prevalence of the use of any anti-hypertensive medications, except for beta-blockers, between PD and PDD (Table 1). Beta-blocker use was found in only four patients, including two patients who used these agents for hypertension and another two patients who used them for tremor. The basal results showed a similar trend to the original data; however, beta-blocker use was significantly associated with PDD (Table 2), and the ORs for dementia of non-neurogenic OH were significant after adjusting for beta-blocker use (Table 3). Because the number of patients prescribed beta-blockers in this study was very small, we were unable to draw any conclusion regarding whether or not beta-blocker use is a risk factors significantly associated with dementia in PD. Further, large-scale clinical studies will be needed to clarify this issue.

We have now revised these results in the Abstract (page 3), Methods (page 7, line 87, line 90-93), and Results (page 10, line 140, line 146-147, page 11, line 151, line 154-157, page 12, line 167-174, page 13, line 185-187) sections and all tables. We also discussed this in the Discussion section (page 14, line 198, page 15, line 201, page 18, line 257-263, line 267-271, page 19, line 272).

Attachment

Submitted filename: Response to Reviewers PLOS ONE [PONE-D-20-22293].docx

Click here for additional data file. (19.6KB, docx)

Decision Letter 1

Pasquale Abete

28 Sep 2020

The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson’s disease

PONE-D-20-22293R1

Dear Dr. TANAKA,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pasquale Abete

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

No further comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have fully addressed my comments.

The correlation between the absence of heart rate response to postural change and dementia in patients affected by Parkinson disease should be an interesting subject to be more extensively treated in the future.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Pasquale Abete

2 Oct 2020

PONE-D-20-22293R1

The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson’s disease

Dear Dr. Tanaka:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Pasquale Abete

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers PLOS ONE [PONE-D-20-22293].docx

    Click here for additional data file. (19.6KB, docx)

    Data Availability Statement

    All relevant data are within the paper.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES